Decibel Therapeutics, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 51.82 million compared to USD 39.34 million a year ago. Basic loss per share from continuing operations was USD 2.49 compared to basic earnings per share from continuing operations of USD 14.84 a year ago.

Diluted loss per share from continuing operations was USD 2.49 compared to USD 19.65 a year ago.